A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with Atherosclerotic cardiovascular disease (ASCVD) or ASCVD- risk equivalents and elevated low density lipoprotein cholesterol (LDL-C)
- Conditions
- elevated levels of cholesterolHypercholesterolemia1008220610013317
- Registration Number
- NL-OMON44477
- Lead Sponsor
- The Medicines Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 30
1. Male or female subjects *18 years of age.
2. History of ASCVD (CHD, CVD or PAD; see APPENDIX A in the protocol) or ASCVD-risk equivalents (type 2 diabetes, familial hypercholesterolemia, and including subjects whose 10-year risk of a CV event assessed by Framingham Risk Score or equivalent has a target LDL-C of <100 mg/dL).
3. Serum LDL-C *1.8 mmol/L (*70 mg/dL) for ASCVD subjects or *2.6 mmol/L (*100 mg/dL) for ASCVD-risk equivalent subjects at screening.
4. Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.
5. Calculated glomerular filtration rate >30 mL/min by estimatedglomerular filtration rate (eGFR) using standardized clinical methodology.
6. Subjects on statins should be receiving a maximally tolerated dose. Maximum tolerated dose is defined as the maximum dose of statin that can be taken on a regular basis without intolerable adverse events. Intolerance to any dose of any statin must be documented as historical AEs attributed to the statin in question in the source documentation and on the Medical History page of the electronic case report form (eCRF) (APPENDIX B from the protocol).
7. Subjects not receiving statin must have documented evidence of intolerance to all doses of at least two different statins (see APPENDIX B from the protocol).
8. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for *30 days before screening with no planned medication or dose change during study participation.
9. Subjects must be willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study.
2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
3. New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection fraction <30%.
4. Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation.
5. Major adverse cardiovascular event within 3 months prior to randomization.
6. Uncontrolled severe hypertension: systolic blood pressure >180mmHg or diastolic blood pressure >110 mmHg prior to randomization despite anti-hypertensive therapy.
7. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in ALT, aspartate aminotransferase (AST), >3x the ULN, or total bilirubin >2x ULN at screening confirmed by a repeat abnormal measurement at least 1 week apart.
8. Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 2 years.
9. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the three years prior to randomization.
10. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of highly effective contraception (failure rate less than 1% per year) (eg combined oral contraceptives, barrier methods, approved contraceptive implant, longterm injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:
a. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) AND more than 55 years of age.
b. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
c. Women who are surgically sterilized at least 3 months prior to enrolment.
11. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
12. Known history of alcohol and/or drug abuse within the last 5 years.
13. Treatment with other investigational products or devices within 30 days or five half lives of the screening visit, whichever is longer.
14. Planned use of other investigational products or devices during the course of the study.
15. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
a. Subjects who are unable to communicate or to cooperate with the investigator.
b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency).
c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study). <br
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoints of this study are the:<br /><br>*Percentage change in LDL-C from baseline to Day 510<br /><br>*Time adjusted percentage change in LDL-C from baseline between Day 90 and Day<br /><br>540. This is the average percentage change in LDL-C from baseline over the<br /><br>period between Day 90 and Day 540.</p><br>
- Secondary Outcome Measures
Name Time Method